# INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

> **NCT03589651** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 83 (actual)

## Conditions studied

- Unresectable or Metastatic Solid Tumors

## Interventions

- **DRUG:** Retifanlimab
- **DRUG:** Epacadostat
- **DRUG:** INCB050465

## Key facts

- **NCT ID:** NCT03589651
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-17
- **Primary completion:** 2022-11-21
- **Final completion:** 2022-11-21
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589651, "INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03589651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*